EPCAM and breast cancer: These nanoprobes not only possess a narrow-band emission peaked at 698 nm under excitation at 254 nm with excellent NIR long afterglow properties and low cytotoxicity but also possess targeting capability toward breast cancer cells (MCF7) which overexpressed EpCAM antigen.